The effect of 6 weeks krill oil/placebo supplementation on heart rate, oxygen consumption and time taken to complete the time trial (pre and post 6 weeks supplementation).

<p>The effect of 6 weeks krill oil/placebo supplementation on heart rate, oxygen consumption and time taken to complete the time trial (pre and post 6 weeks supplementation).</p

The effect of 6 weeks krill oil/placebo supplementation on NK cell cytotoxic activity at 50:1 and 25:1 effector:target cell ratio, before and after exercise.

<p>* indicates significant difference (P<0.05) from baseline values. † indicates significant difference between groups.</p

The effect of 6 weeks krill oil/placebo supplementation on exercise induced cytokine production by PBMCs stimulated with concanavalin A.

<p>* indicates significant difference (P<0.05) from baseline values. † indicates significant difference (P<0.05) between groups.</p

The effect of 6 weeks krill oil/placebo supplementation on plasma IL-6 and TBARS (expressed as MDA concentration) before and after exercise.

<p>* denotes a significant difference (P<0.05) from baseline in both groups.</p

Baseline characteristics of subjects in control and krill oil groups.

<p>Values are mean ± SD.</p

Erythrocyte fatty acid composition in control and krill oil groups at rest pre- and post-supplementation (6 weeks).

<p>Values are mean ± SD. * indicates a significant difference (P<0.05) from baseline values. (c = cis and t = trans)</p

CD11b (A) and CD36 (B) Mean fluorescence intensity on gated cell populations on day 2 and 3 of the control trials.

<p>(A) *** denotes an effect of time for granulocytes and monocytes (P&lt;0.001) (B) * denotes an effect of time for monocytes (P&lt;0.005) and lymphocytes (P&lt;0.05). ■ denotes laboratory meal times. </p

Plasma TG(A) and glucose (B) concentrations on day 2 and 3 of the HIIE and control trials.

<p>Plasma TG(A) and glucose (B) concentrations on day 2 and 3 of the HIIE and control trials.</p

LTTH activity on day 2 of the HIIE and control trials.

<p>* denotes a significant (P&lt;0.05) difference between HIIE and control trials.(N=5).</p